Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344–53. https://doi.org/10.1002/cncr.30258.

Article  CAS  PubMed  Google Scholar 

Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469–74. https://doi.org/10.1038/nature26000.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34(34):4102–9. https://doi.org/10.1200/jco.2016.67.2477.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dimitriou F, Namikawa K, Reijers ILM, Buchbinder EI, Soon JA, Zaremba A, et al. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Ann Oncol. 2022;33(9):968–80. https://doi.org/10.1016/j.annonc.2022.06.004.

Article  CAS  PubMed  Google Scholar 

Elgundi Z, Papanicolaou M, Major G, Cox TR, Melrose J, Whitelock JM, et al. Cancer metastasis: the role of the extracellular matrix and the heparan sulfate proteoglycan perlecan. Front Oncol. 2019;9:1482. https://doi.org/10.3389/fonc.2019.01482.

Article  PubMed  Google Scholar 

Emran AA, Chatterjee A, Rodger EJ, Tiffen JC, Gallagher SJ, Eccles MR, et al. Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy. Trends Immunol. 2019;40(4):328–44. https://doi.org/10.1016/j.it.2019.02.004.

Article  CAS  PubMed  Google Scholar 

Filipski K, Scherer M, Zeiner KN, Bucher A, Kleemann J, Jurmeister P, et al. DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma. J Immunother Cancer. 2021;9(7): e002226. https://doi.org/10.1136/jitc-2020-002226.

Article  PubMed  PubMed Central  Google Scholar 

Forschner A, Battke F, Hadaschik D, Schulze M, Weißgraeber S, Han CT, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma: results of a prospective biomarker study. J Immunother Cancer. 2019;7(1):180. https://doi.org/10.1186/s40425-019-0659-0.

Article  PubMed  PubMed Central  Google Scholar 

Gallo S, Vitacolonna A, Crepaldi T. NMDA receptor and its emerging role in cancer. Int J Mol Sci. 2023;24(3):2540. https://doi.org/10.3390/ijms24032540.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao Y, Yang C, He N, Zhao G, Wang J, Yang Y. Integration of the tumor mutational burden and tumor heterogeneity identify an immunological subtype of melanoma with favorable survival. Front Oncol. 2020;10: 571545. https://doi.org/10.3389/fonc.2020.571545.

Article  PubMed  PubMed Central  Google Scholar 

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment: update 2022. Eur J Cancer. 2022;170:256–84. https://doi.org/10.1016/j.ejca.2022.04.018.

Article  PubMed  Google Scholar 

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics: update 2019. Eur J Cancer. 2020;126:141–58. https://doi.org/10.1016/j.ejca.2019.11.014.

Article  CAS  PubMed  Google Scholar 

Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2019;36(8):2628–9. https://doi.org/10.1093/bioinformatics/btz931.

Article  CAS  PubMed Central  Google Scholar 

Gelis L, Jovancevic N, Bechara FG, Neuhaus EM, Hatt H. Functional expression of olfactory receptors in human primary melanoma and melanoma metastasis. Exp Dermatol. 2017;26(7):569–76. https://doi.org/10.1111/exd.13316.

Article  CAS  PubMed  Google Scholar 

Gowrishankar K, Gunatilake D, Gallagher SJ, Tiffen J, Rizos H, Hersey P. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB. PLoS ONE. 2015;10(4): e0123410. https://doi.org/10.1371/journal.pone.0123410.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He Y, Liu T, Dai S, Xu Z, Wang L, Luo F. Tumor-associated extracellular matrix: how to be a potential aide to anti-tumor immunotherapy? Front Cell Dev Biol. 2021;9: 739161. https://doi.org/10.3389/fcell.2021.739161.

Article  PubMed  PubMed Central  Google Scholar 

Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–55. https://doi.org/10.1038/s41586-019-1922-8.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10. https://doi.org/10.1186/s12943-018-0928-4.

Article  PubMed  PubMed Central  Google Scholar 

Jurmeister P, Wrede N, Hoffmann I, Vollbrecht C, Heim D, Hummel M, et al. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. J Pathol. 2022;256(1):61–70. https://doi.org/10.1002/path.5808.

Article  CAS  PubMed  Google Scholar 

Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18(8):75–84. https://doi.org/10.1080/14737140.2018.1489246.

Article  CAS  Google Scholar 

Kodet O, Lacina L, Krejčí E, Dvořánková B, Grim M, Štork J, et al. Melanoma cells influence the differentiation pattern of human epidermal keratinocytes. Mol Cancer. 2015;14(1):1. https://doi.org/10.1186/1476-4598-14-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss DE, et al. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021;12(1):498. https://doi.org/10.1038/s41467-020-20603-4.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51. https://doi.org/10.1093/neuonc/noab106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu T, Wang S, Xu L, Zhou Q, Singla N, Gao J, et al. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. Sci Immunol. 2020;5(44):eaaz3199. https://doi.org/10.1126/sciimmunol.aaz3199.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maksimovic J, Gordon L, Oshlack A. SWAN: subset-quantile within array normalization for illumina infinium human methylation 450 bead chips. Genome Biol. 2012;13(6):R44. https://doi.org/10.1186/gb-2012-13-6-r44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. Nucleic Acids Res. 2015;43(W1):W566–70. https://doi.org/10.1093/nar/gkv468.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, et al. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. J Immunother Cancer. 2018;6(1):32. https://doi.org/10.1186/s40425-018-0344-8.

Article  PubMed  PubMed Central  Google Scholar 

Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, et al. Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell. 2022;40(1):88–102. https://doi.org/10.1016/j.ccell.2021.11.012.

Article  CAS  PubMed  Google Scholar 

Ning B, Liu Y, Wang M, Li Y, Xu T, Wei Y. The predictive value of tumor mutation burden on clinical efficacy of immune checkpoint inhibitors in melanoma: a systematic review and meta-analysis. Front Pharmacol. 2022;13: 748674. https://doi.org/10.3389/fphar.2022.748674.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pater JL, Loeb M. Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis. Cancer. 1982;50(2):326–31.